Campaigning & Advocacy

As a charity we are actively involved in campaigning on behalf of patients and their carers, which we feel is an important part of the work that we do. We are passionate about doing everything we can to improve the experience of patients throughout their cancer journey.

Our campaigns

We run campaigns throughout the year, and need you to get involved and help raise awareness.

What is campaigning and advocacy?

As a charity we are actively involved in campaigning on behalf of patients and their carers, which we feel is an important part of the work that we do. We are passionate about doing everything we can to improve the experience of patients throughout their cancer journey.

Patient Advocacy Groups

We are involved with a number of organisations and coalitions on your behalf which, through collaborative working, aim to ensure that the collective voice of blood cancer patients is heard.

Working with the pharmaceutical industry

We work with the pharmaceutical industry to ensure that they take the interests of patients into account when developing new drugs and treatments for blood cancer patients.

Health Technology Appraisals

This involves working with bodies such as the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG) to ensure that the views of patients are taken into account when making decisions over access to drugs and treatments.

Latest news on access to COVID-19 treatments

This page sets out which COVID-19 treatments are currently available on the NHS and how to access them.

Read More

Take a Moment to Catch Up

View our latest news and blog articles

December 12th

Leukaemia Care Winter Appeal: Wrapped wishes of gratitude, highlighting the impact of our support

This Winter, we’re wrapping gift tags around Leukaemia Care HQ, filled with heartfelt messages of support and gratitude from those who have benefited from our vital support services....

November 11th

Additional treatment for AML patients now available in Scotland

Leukaemia Care is pleased to announce that newly diagnosed acute myeloid leukaemia (AML) patients with a FLT3 mutation now have access to quizartinib, in combination with chemotherapy, thanks to a decision made by the Scottish Medicines Consortium (SMC) today. ...

October 31st

Leukaemia Care’s response to the 2024 Autumn Budget

"We welcome the increase in the NHS budget. However..." - Colin Dyer, Chief Executive at Leukaemia Care shares the charity's response....